SK13312000A3 - Použitie kabergolínu pri liečbe syndrómu nepokojných nôh - Google Patents

Použitie kabergolínu pri liečbe syndrómu nepokojných nôh Download PDF

Info

Publication number: SK13312000A3
Authority: SK; Slovakia
Prior art keywords: cabergoline; treatment; patients; day; restless legs
Prior art date: 1998-03-27

Application number

SK1331-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Peter Schueler

Original Assignee

Pharmacia And Upjohn Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-27

Filing date

1999-03-24

Publication date

2001-05-10

1999-03-24 Application filed by Pharmacia And Upjohn Company filed Critical Pharmacia And Upjohn Company

2001-05-10 Publication of SK13312000A3 publication Critical patent/SK13312000A3/sk

Links

208000005793 Restless legs syndrome Diseases 0.000 title claims abstract description 161
KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title claims abstract description 113
229960004596 cabergoline Drugs 0.000 title claims abstract description 113
238000011282 treatment Methods 0.000 title claims abstract description 89
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 66
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 65
208000024891 symptom Diseases 0.000 claims description 54
230000007958 sleep Effects 0.000 claims description 45
239000003814 drug Substances 0.000 claims description 40
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 34
238000000034 method Methods 0.000 claims description 34
239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 32
230000000694 effects Effects 0.000 claims description 32
150000003839 salts Chemical class 0.000 claims description 16
230000003416 augmentation Effects 0.000 claims description 12
229940052760 dopamine agonists Drugs 0.000 claims description 12
229960003638 dopamine Drugs 0.000 claims description 11
229940049706 benzodiazepine Drugs 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 7
229940005501 dopaminergic agent Drugs 0.000 claims description 7
239000004089 psychotropic agent Substances 0.000 claims description 7
150000001557 benzodiazepines Chemical class 0.000 claims description 6
239000000556 agonist Substances 0.000 claims description 5
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical group C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 5
238000006243 chemical reaction Methods 0.000 claims description 4
230000002269 spontaneous effect Effects 0.000 claims description 4
238000012360 testing method Methods 0.000 claims description 4
230000002159 abnormal effect Effects 0.000 claims description 3
229960003120 clonazepam Drugs 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 4
208000012195 Reunion island Larsen syndrome Diseases 0.000 claims 1
229940079593 drug Drugs 0.000 description 30
238000002560 therapeutic procedure Methods 0.000 description 21
239000000126 substance Substances 0.000 description 18
230000001965 increasing effect Effects 0.000 description 14
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 14
230000004622 sleep time Effects 0.000 description 14
229940001089 sinemet Drugs 0.000 description 12
230000002354 daily effect Effects 0.000 description 11
150000001875 compounds Chemical class 0.000 description 10
102000005962 receptors Human genes 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
229960004851 pergolide Drugs 0.000 description 9
FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 8
229960001253 domperidone Drugs 0.000 description 8
230000003291 dopaminomimetic effect Effects 0.000 description 8
208000035824 paresthesia Diseases 0.000 description 8
230000000737 periodic effect Effects 0.000 description 8
206010067484 Adverse reaction Diseases 0.000 description 7
108050004812 Dopamine receptor Proteins 0.000 description 7
102000015554 Dopamine receptor Human genes 0.000 description 7
230000006838 adverse reaction Effects 0.000 description 7
229940052740 other dopaminergic agent in atc Drugs 0.000 description 7
238000001907 polarising light microscopy Methods 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
238000009097 single-agent therapy Methods 0.000 description 7
239000003826 tablet Substances 0.000 description 7
230000003247 decreasing effect Effects 0.000 description 6
208000002173 dizziness Diseases 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
229940005483 opioid analgesics Drugs 0.000 description 6
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 5
206010028813 Nausea Diseases 0.000 description 5
230000007423 decrease Effects 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000006872 improvement Effects 0.000 description 5
230000008693 nausea Effects 0.000 description 5
229940088507 permax Drugs 0.000 description 5
206010019233 Headaches Diseases 0.000 description 4
208000018737 Parkinson disease Diseases 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000001961 anticonvulsive agent Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000027455 binding Effects 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
230000005284 excitation Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
231100000869 headache Toxicity 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
208000019116 sleep disease Diseases 0.000 description 4
230000003860 sleep quality Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 3
206010038743 Restlessness Diseases 0.000 description 3
206010041349 Somnolence Diseases 0.000 description 3
206010047700 Vomiting Diseases 0.000 description 3
229940125681 anticonvulsant agent Drugs 0.000 description 3
238000013459 approach Methods 0.000 description 3
229960002802 bromocriptine Drugs 0.000 description 3
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 3
229960004205 carbidopa Drugs 0.000 description 3
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000007717 exclusion Effects 0.000 description 3
-1 opiates Substances 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
229940044601 receptor agonist Drugs 0.000 description 3
239000000018 receptor agonist Substances 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
238000004448 titration Methods 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
230000008673 vomiting Effects 0.000 description 3
230000002618 waking effect Effects 0.000 description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
206010028735 Nasal congestion Diseases 0.000 description 2
208000001431 Psychomotor Agitation Diseases 0.000 description 2
BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000005553 drilling Methods 0.000 description 2
229960002870 gabapentin Drugs 0.000 description 2
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000011221 initial treatment Methods 0.000 description 2
230000005923 long-lasting effect Effects 0.000 description 2
238000002483 medication Methods 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
229940127240 opiate Drugs 0.000 description 2
229940000596 parlodel Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
229960001879 ropinirole Drugs 0.000 description 2
UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 2
230000001953 sensory effect Effects 0.000 description 2
208000022925 sleep disturbance Diseases 0.000 description 2
208000020685 sleep-wake disease Diseases 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical class O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 1
229940081615 DOPA decarboxylase inhibitor Drugs 0.000 description 1
101150049660 DRD2 gene Proteins 0.000 description 1
229940123736 Decarboxylase inhibitor Drugs 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
206010013886 Dysaesthesia Diseases 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
206010027590 Middle insomnia Diseases 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
206010028347 Muscle twitching Diseases 0.000 description 1
RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
229940123257 Opioid receptor antagonist Drugs 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010062519 Poor quality sleep Diseases 0.000 description 1
VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 description 1
SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
101100388144 Xenopus laevis drd5 gene Proteins 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
230000037007 arousal Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000003543 catechol methyltransferase inhibitor Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
238000011976 chest X-ray Methods 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000009193 crawling Effects 0.000 description 1
229940078435 darvocet Drugs 0.000 description 1
239000003954 decarboxylase inhibitor Substances 0.000 description 1
229960004193 dextropropoxyphene Drugs 0.000 description 1
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
QMQBBUPJKANITL-MYXGOWFTSA-N dextropropoxyphene hydrochloride Chemical compound [H+].[Cl-].C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 QMQBBUPJKANITL-MYXGOWFTSA-N 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229960003337 entacapone Drugs 0.000 description 1
JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
229960000240 hydrocodone Drugs 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
206010021654 increased appetite Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
229940073092 klonopin Drugs 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
208000013433 lightheadedness Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229960003587 lisuride Drugs 0.000 description 1
229960004391 lorazepam Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
239000012567 medical material Substances 0.000 description 1
DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
229960003987 melatonin Drugs 0.000 description 1
229960001797 methadone Drugs 0.000 description 1
230000009149 molecular binding Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000036651 mood Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
229960001454 nitrazepam Drugs 0.000 description 1
231100001079 no serious adverse effect Toxicity 0.000 description 1
239000003401 opiate antagonist Substances 0.000 description 1
229960002085 oxycodone Drugs 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000036407 pain Effects 0.000 description 1
229940124641 pain reliever Drugs 0.000 description 1
VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
229960005301 pentazocine Drugs 0.000 description 1
229940011043 percocet Drugs 0.000 description 1
229960001511 pergolide mesylate Drugs 0.000 description 1
UWCVGPLTGZWHGS-ZORIOUSZSA-N pergolide mesylate Chemical compound CS(O)(=O)=O.C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 UWCVGPLTGZWHGS-ZORIOUSZSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
229940035613 prozac Drugs 0.000 description 1
229940001470 psychoactive drug Drugs 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000036387 respiratory rate Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
229960003946 selegiline Drugs 0.000 description 1
230000035807 sensation Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
201000002859 sleep apnea Diseases 0.000 description 1
230000037322 slow-wave sleep Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940066690 talwin Drugs 0.000 description 1
229960003188 temazepam Drugs 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229940000146 vicodin Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK1331-2000A 1998-03-27 1999-03-24 Použitie kabergolínu pri liečbe syndrómu nepokojných nôh SK13312000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7963998P	1998-03-27	1998-03-27
PCT/US1999/004269 WO1999048484A2 (fr)	1998-03-27	1999-03-24	Utilisation de cabergoline pour traiter les impatiences des membres inferieurs

Publications (1)

Publication Number	Publication Date
SK13312000A3 true SK13312000A3 (sk)	2001-05-10

Family

ID=22151836

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1331-2000A SK13312000A3 (sk)	1998-03-27	1999-03-24	Použitie kabergolínu pri liečbe syndrómu nepokojných nôh

Country Status (23)

Country	Link
US (1)	US6114326A (fr)
EP (1)	EP1066038B1 (fr)
JP (1)	JP2002507562A (fr)
KR (1)	KR100597517B1 (fr)
CN (1)	CN1303286A (fr)
AT (1)	ATE313326T1 (fr)
AU (1)	AU747751B2 (fr)
BR (1)	BR9908953A (fr)
CA (1)	CA2320204A1 (fr)
CZ (1)	CZ297284B6 (fr)
DE (1)	DE69929041T2 (fr)
DK (1)	DK1066038T3 (fr)
EA (1)	EA002554B1 (fr)
ES (1)	ES2255255T3 (fr)
HU (1)	HUP0101954A3 (fr)
IL (1)	IL138522A0 (fr)
NO (1)	NO20004799L (fr)
NZ (1)	NZ507176A (fr)
PL (1)	PL343593A1 (fr)
SK (1)	SK13312000A3 (fr)
TR (1)	TR200002759T2 (fr)
WO (1)	WO1999048484A2 (fr)
ZA (1)	ZA200004452B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6375957B1 (en)	1997-12-22	2002-04-23	Euro-Celtique, S.A.	Opioid agonist/opioid antagonist/acetaminophen combinations
ES2412409T3 (es)	1997-12-22	2013-07-11	Euro-Celtique S.A.	Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6477408B1 (en) *	2000-03-07	2002-11-05	Northwestern University	Analysis of muscular activity in neonatal animals to screen for mutations and/or drugs that alter sleep and wake states
GB0007308D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Process for preparing crystalline form \| of cabergoline
GB0007309D0 (en) *	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Crystalline form V\|\| of cabergoline
US6426713B1 (en) *	2000-07-05	2002-07-30	Cirrus Logic, Inc.	Independent control of calibration registers in a multi channel A-D converter
DE10066158B4 (de) *	2000-08-24	2007-08-09	Neurobiotec Gmbh	Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10053397A1 (de) *	2000-10-20	2002-05-02	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
AR031152A1 (es)	2000-10-31	2003-09-10	Upjohn Co	Tratamientos nuevos para el sindrome de piernas inquietas
DE10064453A1 (de) *	2000-12-16	2002-07-04	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20020123503A1 (en) *	2000-12-21	2002-09-05	Malcolm Ross	Cabergoline pharmaceutical compositions and methods of use thereof
JP4453254B2 (ja) *	2001-03-30	2010-04-21	東レ株式会社	レストレス・レッグズ症候群治療薬
US20030065002A1 (en)	2001-05-11	2003-04-03	Endo Pharmaceuticals, Inc.	Abuse-resistant controlled-release opioid dosage form
US20030134844A1 (en) *	2001-10-31	2003-07-17	Pfizer Inc.	Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
US20030176822A1 (en) *	2002-03-12	2003-09-18	Morgenlander Joel C.	Method of treating restless leg syndrome
EP1492505B1 (fr)	2002-04-05	2015-06-03	Euro-Celtique S.A.	Preparation pharmaceutique contenant oxycodone et naloxone
US20040048779A1 (en) *	2002-05-06	2004-03-11	Erwin Schollmayer	Use of rotigotine for treating the restless leg syndrome
JP4498140B2 (ja)	2002-08-30	2010-07-07	協和発酵キリン株式会社	行動障害治療剤
CA2538802C (fr)	2003-09-17	2015-01-27	Xenoport, Inc.	Traitement ou prevention du syndrome des jambes sans repos a l'aide de promedicaments a base d'analogues du gaba
EP1604666A1 (fr)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioides pour le traitement de la bronchopneumopathie chronique obstructive
EP1604667A1 (fr) *	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioides pour le traitement des impatiences des membres inférieurs
KR20060030175A (ko) *	2004-10-05	2006-04-10	경북대학교 산학협력단	무정위성 운동 치료용 약학조성물
GEP20105052B (en) *	2005-01-28	2010-07-26	Euro Celtique Sa	Alcohol resistant dosage forms
EP1695700A1 (fr) *	2005-02-28	2006-08-30	Euro-Celtique S.A.	Forme posologique contenant de l'oxycodone et de la naloxone
EP1702558A1 (fr)	2005-02-28	2006-09-20	Euro-Celtique S.A.	Procédé et dispositif pour évaluer la fonction de l'activité intestinale
WO2007089335A2 (fr) *	2005-12-29	2007-08-09	Lexicon Pharmaceutical Inc.	Derives d'acides amines multicycliques et procedes d'utilisation de ceux-ci
MX2008012781A (es) *	2006-04-03	2008-10-14	Teva Pharma	Uso de rasagilina para el tratamiento de sindrome de piernas inquietas.
WO2008046149A1 (fr) *	2006-10-17	2008-04-24	Biologic Health Solutions Pty Ltd	Compositions à base d'herbes pour la prévention ou le traitement du syndrome des jambes sans repos
EP1952813A1 (fr) *	2007-02-01	2008-08-06	Ferring International Center S.A.	Médicament pour le traitement des endométrioses
EP1987815A1 (fr) *	2007-05-04	2008-11-05	Schwarz Pharma Ag	Compositions pharmaceutiques à base d'agonistes dopaminergiques administrables par voie oro-naso-pharyngale pour la prévention et/ou le traitement de membres sans repos
US7939665B2 (en)	2007-05-04	2011-05-10	Apotex Pharmachem Inc.	Efficient process for the preparation of cabergoline and its intermediates
EP2083008A1 (fr) *	2007-12-07	2009-07-29	Axxonis Pharma AG	Dérivés d'ergoline en tant que piégeurs radicaux sélectifs pour les neurones
BRPI1006186A2 (pt)	2009-03-10	2016-08-23	Euro Celtique Sa	composições farmaceuticas de liberação imediata compreedendo oxicodona e naloxona
RU2701731C2 (ru)	2009-04-01	2019-10-01	Биал-Портела Энд Ка, С.А.	Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения
US8690933B2 (en) *	2009-08-31	2014-04-08	Brigham Young University	System and method for treating symptoms of restless legs syndrome
US20140045900A1 (en)	2011-02-11	2014-02-13	Bial-Portela & Ca, S.A.	Administration regime for nitrocatechols
JP2016525138A (ja)	2013-07-23	2016-08-22	ユーロ−セルティークエス．エイ．	疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
PL232974B1 (pl) *	2015-12-09	2019-08-30	Ofta Spolka Z Ograniczona Odpowiedzialnoscia	Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń
US11103691B2 (en)	2019-10-03	2021-08-31	Noctrix Health, Inc.	Peripheral nerve stimulation for restless legs syndrome
WO2018129351A1 (fr)	2017-01-05	2018-07-12	Shriram Raghunathan	Traitement du syndrome des jambes sans repos ou de l'hyperactivité nerveuse
JP2022551604A (ja)	2019-10-03	2022-12-12	ノクトリックスヘルスインコーポレイテッド	むずむず脚症候群のための末梢神経刺激

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4526892A (en) *	1981-03-03	1985-07-02	Farmitalia Carlo Erba, S.P.A.	Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US5496836A (en) *	1994-05-05	1996-03-05	Mount Sinai School Of Medicine Of The City University Of New York	Use of famotidine and related compounds in the treatment of movement disorders

1999
- 1999-03-24 PL PL99343593A patent/PL343593A1/xx unknown
- 1999-03-24 IL IL13852299A patent/IL138522A0/xx unknown
- 1999-03-24 CZ CZ20003419A patent/CZ297284B6/cs not_active IP Right Cessation
- 1999-03-24 HU HU0101954A patent/HUP0101954A3/hu unknown
- 1999-03-24 SK SK1331-2000A patent/SK13312000A3/sk unknown
- 1999-03-24 EA EA200000994A patent/EA002554B1/ru not_active IP Right Cessation
- 1999-03-24 ES ES99914882T patent/ES2255255T3/es not_active Expired - Lifetime
- 1999-03-24 AT AT99914882T patent/ATE313326T1/de not_active IP Right Cessation
- 1999-03-24 KR KR1020007010666A patent/KR100597517B1/ko not_active Expired - Fee Related
- 1999-03-24 CA CA002320204A patent/CA2320204A1/fr not_active Abandoned
- 1999-03-24 NZ NZ507176A patent/NZ507176A/en unknown
- 1999-03-24 EP EP99914882A patent/EP1066038B1/fr not_active Expired - Lifetime
- 1999-03-24 WO PCT/US1999/004269 patent/WO1999048484A2/fr not_active Ceased
- 1999-03-24 US US09/275,739 patent/US6114326A/en not_active Expired - Fee Related
- 1999-03-24 AU AU33531/99A patent/AU747751B2/en not_active Ceased
- 1999-03-24 TR TR2000/02759T patent/TR200002759T2/xx unknown
- 1999-03-24 CN CN99803305A patent/CN1303286A/zh active Pending
- 1999-03-24 DE DE69929041T patent/DE69929041T2/de not_active Expired - Fee Related
- 1999-03-24 DK DK99914882T patent/DK1066038T3/da active
- 1999-03-24 BR BR9908953-0A patent/BR9908953A/pt not_active Application Discontinuation
- 1999-03-24 JP JP2000537534A patent/JP2002507562A/ja active Pending
2000
- 2000-08-28 ZA ZA200004452A patent/ZA200004452B/xx unknown
- 2000-09-26 NO NO20004799A patent/NO20004799L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1066038A2 (fr)	2001-01-10
BR9908953A (pt)	2000-12-05
AU3353199A (en)	1999-10-18
NZ507176A (en)	2003-09-26
DK1066038T3 (da)	2006-04-24
KR20010052222A (ko)	2001-06-25
ZA200004452B (en)	2002-02-27
WO1999048484A2 (fr)	1999-09-30
PL343593A1 (en)	2001-08-27
NO20004799D0 (no)	2000-09-26
AU747751B2 (en)	2002-05-23
EA002554B1 (ru)	2002-06-27
WO1999048484A3 (fr)	1999-11-25
CZ20003419A3 (cs)	2002-01-16
ES2255255T3 (es)	2006-06-16
US6114326A (en)	2000-09-05
NO20004799L (no)	2000-10-11
CA2320204A1 (fr)	1999-09-30
JP2002507562A (ja)	2002-03-12
DE69929041D1 (de)	2006-01-26
CN1303286A (zh)	2001-07-11
CZ297284B6 (cs)	2006-10-11
KR100597517B1 (ko)	2006-07-10
EP1066038B1 (fr)	2005-12-21
TR200002759T2 (tr)	2001-02-21
HUP0101954A3 (en)	2002-09-30
IL138522A0 (en)	2001-10-31
DE69929041T2 (de)	2006-07-20
ATE313326T1 (de)	2006-01-15
HUP0101954A2 (hu)	2001-12-28
EA200000994A1 (ru)	2001-02-26

Publication	Publication Date	Title
SK13312000A3 (sk)	2001-05-10	Použitie kabergolínu pri liečbe syndrómu nepokojných nôh
Wetter et al.	1997	Restless legs and periodic leg movements in sleep syndromes
Wagner et al.	1996	Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome
Herman et al.	1987	Naltrexone decreases self‐injurious behavior
Walters et al.	1993	Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo
TWI326214B (en)	2010-06-21	Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
Shelton et al.	1995	Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs
WO2003092682A1 (fr)	2003-11-13	Utilisation de zonisamide dans le traitement de l'obesite et des troubles alimentaires
KR20150091323A (ko)	2015-08-10	시상피질 율동부정의 치료
US20220023316A1 (en)	2022-01-27	Methods for the treatment of depression
WO2000025821A1 (fr)	2000-05-11	Methode permettant de traiter et de diagnostiquer le syndrome des impatiences des membres inferieurs et dispositif correspondant
EA016007B1 (ru)	2012-01-30	Лечение болезни паркинсона, обструктивного синдрома апноэ во сне, слабоумия с тельцами льюи, сосудистой деменции с помощью не содержащих имидазол алкиламиновых лигандов гистаминовых н-рецепторов
Folks et al.	1998	Sedative hypnotics and sleep
JP2003521487A (ja)	2003-07-15	ミオパシー関連性の覚醒障害を矯正することが意図される医薬品を製造するためのモダフィニルの使用
US4992443A (en)	1991-02-12	Method of treating motion sickness
LIEBERMAN et al.	1985	Neuromuscular effects of monoamine oxidase inhibitors
EP1477168A1 (fr)	2004-11-17	Utilisation de la cabergoline pour traiter le syndrome de l'acroparesthésie nocturne
MXPA00009395A (en)	2001-07-09	Use of cabergoline in the treatment of restless legs syndrome
Tatlow et al.	1954	The clinical effects of chlorpromazine on dyskinesia
Williams	1997	Tramadol hydrochloride: something new in oral analgesic therapy
Phero	1984	Pharmacotherapy for chronic facial pain
Fantini et al.	2012	Sleep and violence
Harris	1981	Extrapyramidal Side Effects
HK1037324A (en)	2002-02-08	Use of cabergoline in the treatment of restless legs syndrome
Nicolodi	1996	Differential sensitivity to morphine challenge in migraine sufferers and headache‐exempt subjects